Previous 10 | Next 10 |
Inhibrx Receives FDA Orphan-Drug Designation for INBRX-109 in Chondrosarcoma - Orphan-drug designation follows fast track designation granted to INBRX-109 in conventional chondrosarcoma - Preliminary median progression-free survival (PFS) of 7.4 months and disease control ra...
Inhibrx (NASDAQ:INBX): Q3 GAAP EPS of -$0.54 beats by $0.03. Revenue of $2.53M (-57.1% Y/Y) beats by $1.53M. Press Release For further details see: Inhibrx EPS beats by $0.03, beats on revenue
Inhibrx Reports Third Quarter 2021 Financial Results and Recent Corporate Highlights PR Newswire SAN DIEGO , Nov. 9, 2021 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and a strong emerging p...
Inhibrx Announces Presentations at SITC 2021 PR Newswire SAN DIEGO , Nov. 3, 2021 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and an emerging pre-clinical pipeline, announced today that the...
Inhibrx Announces Participation in Upcoming Scientific and Investor Conferences PR Newswire SAN DIEGO , Nov. 1, 2021 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and an emerging pre-clinical pipe...
Inhibrx Strengthens Leadership Team with Three Key Executive Hires and Announces Appointment of Kristiina Vuori, M.D., Ph.D. to its Board of Directors PR Newswire SAN DIEGO , Oct. 28, 2021 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), announced the appointment of...
Gainers: Nutriband (NTRBW) +97%. Nutriband (OTCQB:NTRB) +41%. R. R. Donnelley & Sons (NYSE:RRD) +38%. Tiptree (NASDAQ:TIPT) +27%. Inhibrx (NASDAQ:INBX) +24%. Weatherford (NASDAQ:WFRD) +20%. NRx Pharmaceuticals (NASDAQ:NRXP) +19%. Xiaobai Maimai (NASDAQ:HX) +19%. Ocugen (NASDAQ:OCGN) +16%....
Shares of Inhibrx (NASDAQ: INBX) , a clinical-stage biotechnology company, jumped when the market opened today. Investors excited about the company's latest clinical trial readout pushed the stock 26.8% higher as of 11:29 a.m. on Tuesday. Today, Inhibrx reported top-line data fr...
Gainers: Nutriband (NTRBW) +84%, Nutriband (OTCQB:NTRB) +38%, Inhibrx (NASDAQ:INBX) +29%, Titan Pharmaceuticals (NASDAQ:TTNP) +14%, Quanterix (NASDAQ:QTRX) +17%. Losers: Organogenesis (NASDAQ:ORGO) -17%, Trevi Therapeutics (NASDAQ:TRVI) -11%,&...
INBRX-101 Shows Favorable Safety Profile in Patients with Alpha-1 Antitrypsin Deficiency and Demonstrates the Potential to Achieve Normal Alpha-1 Antitrypsin Levels with Monthly Dosing -- Interim results from the Phase 1 study show a favorable safety and tolerability profile wit...
News, Short Squeeze, Breakout and More Instantly...
Inhibrx Inc. Company Name:
INBX Stock Symbol:
NASDAQ Market:
2024-07-23 06:30:08 ET JMP Securities analyst issues MARKET PERFORM recommendation for INBX on July 23, 2024 04:40AM ET. The previous analyst recommendation was Outperform. INBX was trading at $13.49 at issue of the analyst recommendation. The overall analyst consensus :...
A look at the top 10 most actives in the United States Maxeon Solar Technologies Ltd. (MAXN) rose 3.6% to $0.2493 on volume of 118,503,418 shares Qualigen Therapeutics Inc. (QLGN) rose 94.8% to $0.4 on volume of 100,863,101 shares AgriFORCE Growing Systems Ltd. (AGRI) rose 20.0% to $0.098...
Smart Share Global Limited (EM) is expected to report for Q1 2024 American Rebel Holdings Inc. (AREB) is expected to report for Q1 2024 First Republic Bank (San Francisco, California) (FRCB) is expected to report for Q1 2024 Spark Networks SE (LOVLQ) is expected to report for Q1 2024 ...